Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide‐Spectrum SARS‐CoV‐2, in Healthy Subjects Severe acute respiratory syndrome caused by the coronavirus (SARS-CoV-2) in the COVID-19 pandemic has highlighted the need for effective treatments, as rapid viral mutations complicate therapeutic de....

🚨New data on inhaled siRNA therapies for respiratory viruses!
ascpt.onlinelibrary.wiley.com/doi/10.1111/...
#COVID19 #SARSCoV2 #Antivirals #ClinicalTrials #RNAtherapy #Phase1Trial

Sumitomo Pharma & NIBIOHN collaborate on universal flu vaccine Phase 1 trials. 🌍💉 #協力研究 #インフルエンザ総合投与 #Phase1Trial https://fefd.link/E6Vfn